US Patent 11407732 Tricyclic degraders of Ikaros and Aiolos
Patent 11407732 was granted and assigned to C4 Therapeutics on August, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 18 Sep, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 31 Jul, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
0
Edits on 1 Nov, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 23 Apr, 2023
Golden AI
Infobox
Edits on 29 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
114077320
Date of Patent
August 9, 2022
0Patent Application Number
174986170
Date Filed
October 11, 2021
0Patent Primary Examiner
Edits on 27 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
114077320
Date of Patent
August 9, 2022
0Patent Application Number
174986170
Date Filed
October 11, 2021
0Patent Primary Examiner
Edits on 23 Sep, 2022
Golden AI
Infobox
Edits on 10 Aug, 2022
Golden AI
Edits made to:
Infobox (+10 properties)
Article (+146 characters)
US Patent 11407732 Tricyclic degraders of Ikaros and Aiolos
Article
Tricyclic cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway for therapeutic applications are described.
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11407732
Date of patent
August 9, 2022
Patent application number
17498617
Date Filed
October 11, 2021
Patent primary examiner
Find more entities like US Patent 11407732 Tricyclic degraders of Ikaros and Aiolos
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.